Early-onset Alzheimer’s Disease Phenotypes: Neuropsychology and Neural Networks

Overview

This study attempts to identify two types of AD by using clinical and cognitive tasks and brain imaging. The subtypes of AD are separated into a "typical" group (memory loss) and a "variant" group (language, visuospatial, and other cognitive difficulties). Performance on the clinical tasks and brain imaging will be compared among the young-onset Alzheimer's disease group, a late-onset Alzheimer's disease group, and a control group.

Full Title of Study: “Early-onset Alzheimer’s Disease Phenotypes: Neuropsychology and Neural Networks”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 31, 2021

Detailed Description

Unlike the usual late-onset Alzheimer's disease (LOAD), early-onset AD (EOAD), with onset before age 65, includes a high percentage of phenotypic variants. These non-familial, variants (vEOAD) present, not with progressive memory loss, but with language, visuospatial, or other cognitive difficulties. AD is now understood as a disorder that manifests with disturbed cognition reflecting disturbed neural networks. A multivariate analysis of neuropsychological tests, the "gold standard" for objectively defining neurocognitive impairments, coupled with structural and functional neuroimaging analysis of connectomes, can identify the neurocognitive-neural network profiles of vEOAD patients, compared to those with typical AD. This knowledge can increase our understanding of the heterogeneity of AD and how it causes disease. This study hopes to show that vEOAD constitutes a "Type 2 AD", by (1) defining the neuropsychological components of Type 2 AD, and (2) understanding the anatomy and atrophy of the brains of vEOAD patients. Together, these components can outline the neurocognitive-neural network profile of Type 2 AD. In addition to information that can help in the diagnosis and management of EOAD, this study can stimulate novel research into the reasons for this neurobiological heterogeneity in AD and could potentially lead to interventions based on alternate neurocognitive-neural network profiles.

Arms, Groups and Cohorts

  • Early-onset Alzheimer’s disease
    • This group will include 90 patients who have been diagnosed with clinically probable early-onset Alzheimer’s disease by the UCLA Neurology Clinic (60 variant phenotypes; 30 typical amnestic).
  • Alzheimer’s disease
    • This group will include 30 patients who have been diagnosed with clinically probable Alzheimer’s disease (typical late-onset AD)
  • Controls
    • Healthy age-matched individuals without clinically significant cognitive impairments will be enrolled into this study.

Clinical Trial Outcome Measures

Primary Measures

  • Alzheimer’s disease Subtype
    • Time Frame: Performed at baseline
    • Neuropsychological testing results for use in a two-stage multivariate diagnostic method that combines the (weighted) test results in order to best discriminate Type 2 AD and typical AD.

Secondary Measures

  • Change in overall Neurological profile
    • Time Frame: Performed at baseline and 1-year follow-up visit
    • Change in performance on neurological tasks between baseline visit and follow-up visit.
  • Brain atrophy in MRI – Magnetic Resonance Imaging of the brain
    • Time Frame: Performed at baseline visit
    • Images from initial MRI scan taken at baseline visit will be analyzed for atrophy and white matter tract integrity
  • Change in overall Neuropsychological profile
    • Time Frame: Performed at baseline and 1-year follow-up visit
    • Change in neuropsychological performance over time.

Participating in This Clinical Trial

Inclusion criteria for patients with Alzheimer's disease (AD): 1. Meet criteria for AD. 2. Meet clinical criteria for either typical amnestic AD or variant phenotypes of early-onset (EOAD, or "Type 2 AD"). 3. Mild-moderate dementia severity 4. Sufficient English fluency to complete neuropsychological testing in English. 5. Ability to provide consent for participation, or willingness to provide assent and a legally-authorized representative willing to provide surrogate consent. 6. Availability of a caregiver informant for participation Exclusion criteria for patients with Alzheimer's disease (AD): 1. Complicating medical illnesses. 2. Significant primary visual impairments. 3. Major psychiatric illness not due to the dementia. 4. Confounding medications. Inclusion criteria for control participants: 1. Score 28/30 or higher on the Folstein Mini-Mental Status Exam. 2. Age 40-85 years old 3. Able to provide consent for participation and express willingness to participate in one-year follow-up visits. 4. Have sufficient English fluency to complete neuropsychological testing in English. Exclusion criteria for control participants: 1. Complicating medical illnesses. 2. Significant primary visual impairments. 3. Major psychiatric illness not due to the dementia. 4. Confounding medications.

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of California, Los Angeles
  • Collaborator
    • National Institute on Aging (NIA)
  • Provider of Information About this Clinical Study
    • Principal Investigator: Mario F. Mendez, Professor of Neurology and Psychiatry – University of California, Los Angeles
  • Overall Official(s)
    • Mario F Mendez, MD, PhD, Principal Investigator, University of California, Los Angeles
  • Overall Contact(s)
    • Youssef I Khattab, BA, (310)-478-3711, YKhattab@mednet.ucla.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.